Tag: Diabetes: Type II
Semaglutide Doubles Risk for Nonarteritic Anterior Ischemic Optic Neuropathy
Findings seen for patients with type 2 diabetes during a five-year period
Study Quantifies Global T2DM, CVD Burdens Attributable to Sugary Drinks
In 2020, 9.8 percent of all incident type 2 diabetes cases and 3.1 percent of cardiovascular disease cases were attributable to sugar-sweetened beverages
FDA Approves First Generic Liraglutide Once-Daily Injection
Approval is part of FDA effort to prioritize generic approvals for drugs in short supply
High Acceptance Seen for Liver Stiffness Test With Routine Retina Scan in T2DM
77.2 percent of those eligible accepted assessment; high proportion did not have elevated liver stiffness measurement on second transient elastography
Empagliflozin Not Tied to Risk for New Nonproliferative Diabetic Retinopathy
Empagliflozin may lower risk for diabetic retinopathy progression
Vitamin D Supplementation Does Not Reduce Risk for T2DM in Healthy Seniors
Supplementation does not reduce risk among older adults who are not at high risk for type 2 diabetes
U-Shaped Association Seen for Alcohol Consumption, Cardiometabolic Disease
However, no evidence seen for causal association between alcohol consumption and risk for coronary heart disease, type 2 diabetes
Increased Consumption of Dark Chocolate Linked to Lower Risk for T2DM
Linear dose-response association seen between intake of dark chocolate and risk for type 2 diabetes
Younger Age at Diabetes Diagnosis Tied to Higher Risk for Later Dementia
Risk tripled for individuals diagnosed at younger than 50 years who are living with obesity
AHA: Intensive Strategy for Lowering Systolic BP Beneficial in Type 2 Diabetes
Significantly lower incidence of major cardiovascular events seen with intensive- versus standard-treatment strategy
